Cost-effectiveness of boceprevir in patients previously treated for chronic hepatitis C genotype 1 infection in the United States.
about
A systematic review of economic evaluations of treatments for borderline personality disorderValue of Treating All Stages of Chronic Hepatitis C: A Comprehensive Review of Clinical and Economic EvidenceOutcomes and Costs of Treating Hepatitis C Patients in the Era of First Generation Protease Inhibitors - Results from the PAN Study.Cost-effectiveness of hepatitis C treatment using generic direct-acting antivirals available in IndiaDirect-acting antivirals for chronic hepatitis C.Achieving sustained virologic response in hepatitis C: a systematic review of the clinical, economic and quality of life benefitsCost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United StatesAn observational study of the direct costs related to hospital admissions, mortality and premature death associated with liver disease in Portugal.Why We Should Be Willing to Pay for Hepatitis C Treatment.Incremental cost-effectiveness pharmacoeconomic assessment of hepatitis C virus therapy: an approach for less wealthy members of the common market.How to optimize current therapy of HCV genotype 1 infection with boceprevir.The cost-effectiveness of boceprevir for hepatitis C.Cost-effectiveness of protease inhibitor based regimens for chronic hepatitis C: a systematic review of published literature.Outcomes, costs and cost-effectiveness of treating hepatitis C with direct acting antivirals.Systematic Review of Modelling Approaches for the Cost Effectiveness of Hepatitis C Treatment with Direct-Acting Antivirals.Cost-effectiveness of elbasvir/grazoprevir use in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and chronic kidney disease in the United States.The cost-effectiveness of testing for NS5a resistance-associated polymorphisms at baseline in genotype 1a-infected (treatment-naïve and treatment-experienced) subjects treated with all-oral elbasvir/grazoprevir regimens in the United States.Optimal timing of hepatitis C treatment for patients on the liver transplant waiting list.Cost-effectiveness analysis of sofosbuvir plus peginterferon/ribavirin in the treatment of chronic hepatitis C virus genotype 1 infection.Changing Cycle Lengths in State-Transition Models: Challenges and SolutionsCost-effectiveness of strategy-based approach to treatment of genotype 1 chronic hepatitis C.Hepatitis C Disease Burden in the United States in the era of oral direct-acting antivirals.Predictors of poor mental and physical health status among patients with chronic hepatitis C infection: the Chronic Hepatitis Cohort Study (CHeCS).Assessing the Effect of Potential Reductions in Non-Hepatic Mortality on the Estimated Cost-Effectiveness of Hepatitis C Treatment in Early Stages of Liver Disease.Cost-effectiveness analysis of sofosbuvir-based regimens for chronic hepatitis C.Transplanting HCV-positive livers into HCV-negative patients with preemptive antiviral treatment: A modeling study.Hepatitis C virus re-treatment in the era of direct-acting antivirals: projections in the USA.Should we treat acute hepatitis C? A decision and cost-effectiveness analysis.Theoretical Foundations and Practical Applications of Within-Cycle Correction Methods.Cost-effectiveness analysis of elbasvir-grazoprevir regimen for treating hepatitis C virus genotype 1 infection in stage 4-5 chronic kidney disease patients in France.Cost/Benefit of Hepatitis C Treatment: It Does Not End with SVR.Cost-effectiveness of diagnostic and therapeutic interventions for chronic hepatitis C: a systematic review of model-based analyses.Direct-acting antivirals for chronic hepatitis C
P2860
Q27010205-0E4616A1-95B5-4AA0-96CE-302B0C097FE7Q28072257-13AAEA27-2CE1-4134-BDF5-D183FDF24647Q30376341-DDE12A47-4926-49DF-A854-AF77AA90806AQ33698956-4CFDB913-EE78-4F17-A247-51C6E08807F2Q34557595-08586BA2-45B6-4781-AD06-6DD33DFE508AQ34987336-4F1BD956-23B0-46C0-9651-F0DEE183E908Q35619161-09EA2A77-7FBC-4051-87EB-CB8A0BB8D719Q35914175-05AD8489-421F-4F1E-9E4A-DF1D23E5A31BQ36075161-E06D370F-620E-49B0-943F-F179395AC177Q37555115-1BE6970F-42B3-4DE9-99D8-13F72A0CFA46Q38174241-897F8A50-B2FB-48FE-AD26-182CBD30A5FBQ38202682-73B4BBBE-FB83-423E-B211-C4B5650A14BAQ38206573-6B318F32-78EA-430F-A273-2A4EAE20532EQ38470584-BF3105DC-2563-4C16-80FB-C34B1ED65995Q38691333-6841E3BF-6731-4D8D-BF98-10B89A5FB263Q39102936-42DED06A-EA2F-4E5D-91A9-25C60292F947Q39137372-0C91ECE5-C69A-446F-AB6D-890967C0B6CEQ39139767-5A06EFF7-82EF-4E4A-9994-95FBD5E20A7EQ39153261-D4EF5CA5-E59A-4622-A9DC-DE1DED66EC71Q39638320-3346A492-7315-4ADD-9C8F-E7751FD0EDB9Q39910149-5B413DAD-AAA5-455C-9A25-DF74A2FF2572Q40528873-F56CBF33-F0E5-45D1-9242-44C42B046AC1Q41746574-B8239B92-2750-4467-9C58-C61B6D9DA029Q42048758-483576D5-CB0F-4DF2-8655-D40AB76F54FFQ45050419-CACCC40C-33FE-4E9E-8D89-59D0226F5B65Q46626377-A994605A-B71F-4895-9A11-BE281944440BQ47548368-85E47C3A-5415-4038-B00A-6934215DFE08Q47603693-2004620C-BC8E-48FF-B687-A0B0AACFC48BQ48787840-1433342A-5035-4AC8-8077-02F738463C7CQ52653977-EB5F1681-97B9-43E0-A60F-A2098CF2D647Q54254113-37219A9D-CC73-42DB-B910-83953A3259D7Q55280669-04B6E47C-0BD1-4F75-9CF0-7419938A8EC0Q57389418-068E2734-9B4C-452A-BD9E-AA04168EC722
P2860
Cost-effectiveness of boceprevir in patients previously treated for chronic hepatitis C genotype 1 infection in the United States.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on September 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Cost-effectiveness of boceprev ...... nfection in the United States.
@en
Cost-effectiveness of boceprev ...... nfection in the United States.
@nl
type
label
Cost-effectiveness of boceprev ...... nfection in the United States.
@en
Cost-effectiveness of boceprev ...... nfection in the United States.
@nl
prefLabel
Cost-effectiveness of boceprev ...... nfection in the United States.
@en
Cost-effectiveness of boceprev ...... nfection in the United States.
@nl
P2093
P2860
P1433
P1476
Cost-effectiveness of boceprev ...... nfection in the United States.
@en
P2093
Antoine C El Khoury
Bruce Bacon
Cliff Brass
Elamin H Elbasha
Jagpreet Chhatwal
Margaret Burroughs
Shannon A Ferrante
P2860
P304
P356
10.1016/J.JVAL.2013.07.006
P577
2013-09-01T00:00:00Z